System for In Vivo Biosensing Based on the Optical Response of Electronic Polymers

• US 20100324383A1
• Filed: 12/05/2007
• Published: 12/23/2010
• Est. Priority Date: 12/07/2006
• Status: Active Grant

• Current Assignee: The Ohio State University Research Foundation
• Original Assignee: The Ohio State University Research Foundation
• Inventors: Nemzer, Louis R., Epstein, Arthur J.
• Granted Patent: US 8,326,389 B2
• Time in Patent Office: Days
• US Class Current: 600/316
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/1459 invasive, e.g. introduced into the body by a catheter A61B5/1464 takes precedence
• CPC Class Codes: A61B 5/14735 comprising an immobilised reagent
• CPC Class Codes: A61B 5/14865 invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
• CPC Class Codes: A61B 5/681 Wristwatch-type devices

Abstract

A system for continuous in vivo biosensing of specific analyte molecule concentrations based on the dynamic optical properties of electronic polymers is disclosed. The biosensor system includes at least one implant member subcutaneously exposed to the interstitial fluid of the subject, and a reader member at least temporarily positioned over the implant member to probe it with light of specific wavelengths through the skin. The system has many potential applications, including the real-time monitoring of blood glucose levels in diabetics as a method to supplement or replace conventional capillary blood testing.

Claims

1. A system for in vivo biosensing of one or more target analyte molecules in a subject, the system comprising:

at least one implant member configured to be completely implanted in the subject'"'"'s body and to be exposed to the one or more target analyte molecules in the subject'"'"'s body,

the implant member including a reflective substrate having deposited thereon at least one polymer and at least one sensitizing agent that causes an oxidation-reduction reaction with the polymer in the presence of the target analyte molecule;

at least one reader member separate from the implant member and configured to be at least temporarily positioned external to the subjects'"'"' body and adjacent to the implant member,

the reader member being configured;

i) to emit light having one or more specific wavelengths, and ii) to detect a reflected signal from the implant member; and

at least one data system configured to determine a concentration of the target analyte molecule.

4. The biosensor system of claim 1, wherein the reader system is configured to substantially continuously detect the reflected signal from the implant member.

6. The biosensor system of claim 1, wherein the polymer is present as a thin film and/or fiber network material on the reflective substrate.

7. The biosensor system of claim 1, wherein the sensitizing agent is covalently bonded to, or immobilized on, the polymer on the implant member.

9. The biosensor system of claim 1, wherein the polymer is an electronic polymer having an optical absorption spectrum in the ultraviolet-visible-near infrared (UV-VIS-NIR) range that is dependent on the polymer'"'"'s oxidation state.

10. The biosensor system of claim 1, wherein the polymer comprises polyaniline, or oligomers thereof.

11. The biosensor system of claim 1, wherein the sensitizing agent comprises one or more enzymes.

13. The biosensor system of claim 1, wherein the sensitizing agent comprises an oxidoreductase and the analyte is the associated substrate.

14. The biosensor system of claim 1, wherein the analyte molecule is glucose, and the sensitizing agent comprises glucose oxidase (GOx).

15. The biosensor system of claim 1, wherein the analyte molecule is cholesterol, and the sensitizing agent comprises cholesterol oxidase.

16. The biosensor system of claim 1, wherein the analyte molecule is ethanol, and the sensitizing agent comprises alcohol oxidase.

17. The biosensor system of claim 1, wherein the polymer incorporates segments of polyaniline that have repeat lengths of at least four aniline rings, or oligomers thereof.

19. The biosensor system of claim 1, wherein the electronic polymer incorporates pendant groups comprised of aniline that has repeat lengths of at least four aniline rings, or oligomers thereof.

20. The biosensor system of claim 1, wherein the polymer incorporates segments of pyridine that have repeat lengths of at least four pyridine rings, or oligomers thereof.

21. The biosensor system of claim 1, wherein the polymer incorporates segments of pyrazine that have repeat lengths of at least four pyrazine rings, or oligomers thereof.

24. The biosensor system of claim 1, wherein the polymer incorporates pendent groups comprised of pyridine oligomer that has repeat lengths of at least four pyridine rings, or oligomers thereof.

25. The biosensor system of claim 1, wherein the polymer incorporates pendent groups comprised of pyrazine oligomer that has repeat lengths of at least four pyrazine rings, or oligomers thereof.

27. The biosensor system of claim 1, wherein the reader member is configured:

i) to focus a reference beam signal on a region of the implant member that is free of the sensitizing agent, and

ii) to distinguish changes due to the presence of interferants in the interstitial fluid in the subject.

29. The biosensor system of claim 1, wherein the implant member includes a plurality of sections, each section being configured to show how ratios of the reflected light from each section change over time and to determine the corresponding analyte concentration.

30. The biosensor system of claim 29, wherein the reader member includes at least one light source and at least one detector associated with each section,

whereby each light source is configured to send light to each section, and whereby each detector is configured to receive light from each section.

32. The biosensor system of claim 30, wherein the implant member further includes a coating that is optimized for each section so that undesired wavelengths are not reflected as strongly as desired wavelengths.

33. The biosensor system of claim 1, wherein the implant member further includes a coating configured to keep interferants from interacting with the implant member.

34. The biosensor system of claim 1, wherein the implant member further includes a coating configured to prevent damage due to the subject'"'"'s immune response.

39. The biosensor system of claim 1, wherein the sensitizing agent comprises one or more of:

malate oxidase, hexose oxidase, glucose oxidase, cholesterol oxidase, aryl-alcohol oxidase, L-gulonolactone oxidase, galactose oxidase, pyranose oxidase, L-sorbose oxidase, pyridoxine 4-oxidase, alcohol oxidase, catechol oxidase, (S)-2-hydroxy-acid oxidase, ecdysone oxidase, choline oxidase, secondary-alcohol oxidase, 4-hydroxymandelate oxidase, long-chain-alcohol oxidase, glycerol-3-phosphate oxidase, thiamine oxidase, hydroxyphytanate oxidase, nucleoside oxidase, N-acylhexosamine oxidase, polyvinyl-alcohol oxidase, D-arabinono-1,4-lactone oxidase, vanillyl-alcohol oxidase, nucleoside oxidase, D-mannitol oxidase, and xylitol oxidase.

2. (canceled)

3. (canceled)

5. (canceled)

8. (canceled)

12. (canceled)

18. (canceled)

22. (canceled)

23. (canceled)

26. (canceled)

28. (canceled)

31. (canceled)

35. (canceled)

36. (canceled)

37. (canceled)

38. (canceled)

40. A method for in vivo biosensing of specific analyte molecule concentrations in a subject, comprising:

a) completely implanting at least one implant member in the subject'"'"'s body wherein the implant member is exposed to specific analyte molecule concentrations in the subject,

the implant including a reflective substrate having deposited thereon at least one polymer and at least one sensitizing agent that causes an oxidation-reduction reaction with the polymer in the presence of the target analyte molecule;

b) at least temporarily positioning a reader member external to the subjects'"'"' body and adjacent to the implant member, the reader member emitting light of specific wavelengths and detecting a reflected signal from the implant member; and

c) determining a concentration of the target analyte molecule from the reflected signal.

42. The method of claim 40, further including emitting with multiple beams of light of specific wavelengths and detecting reflected signals from the implant member.

45. The method of claim 40, wherein the reader member focuses a reference beam signal on a region of the implant member that is free of the sensitizing agent, and distinguishes changes due to the presence of interferants in the interstitial fluid in the subject.

47. The method of claim 40, wherein the implant member includes a plurality of sections, each section being configured to show how ratios of the reflected light from each section change over time and to determine the corresponding analyte concentration.

48. The method of claim 40, wherein the reader member includes at least one light source and at least one detector associated with each section, whereby each light source sends light to each section, and whereby each detector receives light from each section.

55. The method of claim 40, wherein the polymer comprises an electronic polymer.

56. The method of claim 40, wherein the polymer is an electronic polymer having an optical absorption spectrum in the ultraviolet-visible-near infrared range that is dependent on the polymer'"'"'s oxidation state.

57. The method of claim 40, wherein the polymer comprises one or more of:

polyaniline, or oligomers thereof;

the polymer incorporates segments of polyaniline that have repeat lengths of at least four aniline rings, or oligomers thereof;

the polymer comprises an oligomer of aniline incorporating a minimum of four aniline rings;

the polymer incorporates pendent groups comprised of polyaniline oligomer that has repeat lengths of at least four aniline rings, or oligomers thereof;

the polymer incorporates segments of pyridine that have repeat lengths of at least four pyridine rings, or oligomers thereof;

the polymer incorporates segments of pyrazine that have repeat lengths of at least four pyrazine rings, or oligomers thereof;

the polymer comprises an oligomer of pyridine incorporating a minimum of four pyridine rings;

the polymer comprises an oligomer of pyrazine incorporating a minimum of four pyrazine rings;

the polymer incorporates pendent groups comprised of pyridine oligomer that has repeat lengths of at least four pyridine rings, or oligomers thereof; and

the polymer incorporates pendent groups comprised of pyrazine oligomer that has repeat lengths of at least four pyrazine rings, or oligomers.

61. The method of claim 40, wherein the analyte molecule is glucose, and the sensitizing agent comprises glucose oxidase (GOx).

41. (canceled)

43. (canceled)

44. (canceled)

46. (canceled)

49. (canceled)

50. (canceled)

51. (canceled)

52. (canceled)

53. (canceled)

54. (canceled)

58. (canceled)

59. (canceled)

60. (canceled)

62. (canceled)